triazoles has been researched along with Autism Spectrum Disorder in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anagnostou, E; Ashford, E; Deol-Bhullar, G; Jacob, S; McCracken, J; Meyenberg, C; Murphy, D; Sanders, K; Smith, J; Veenstra-VanderWeele, J; Wandel, C; Wiese, T | 1 |
| Anagnostou, E; Ashford, E; Chatham, C; Clinch, S; Hollander, E; Jacob, S; Jou, R; McCracken, J; McNamara, N; Murphy, D; Murtagh, L; Noeldeke, J; Sanders, K; Sikich, L; Smith, J; Tobe, R; Veenstra-VanderWeele, J | 1 |
| Gleissl, T; Hollander, E; Jacob, S; Jou, R; McNamara, N; Murtagh, L; Sanders, K; Sikich, L; Smith, J; Squassante, L; Tobe, R; Veenstra-VanderWeele, J; Wandel, C | 1 |
| Bissantz, C; Bruns, A; Dolente, C; Goetschi, E; Grundschober, C; Jakob-Roetne, R; Künnecke, B; Mueggler, T; Muster, W; Parrott, N; Pinard, E; Ratni, H; Risterucci, C; Rogers-Evans, M; Schnider, P; von Kienlin, M | 1 |
| Iwata, M; Kaneko, K | 1 |
| Bolognani, F; Del Valle Rubido, M; Derks, M; Fontoura, P; Khwaja, O; Murtagh, L; Sevigny, J; Squassante, L; Umbricht, D; Wandel, C | 1 |
3 trial(s) available for triazoles and Autism Spectrum Disorder
| Article | Year |
|---|---|
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Autism Spectrum Disorder; Benzodiazepines; Communication Disorders; Double-Blind Method; Female; Humans; Male; Pyridines; Treatment Outcome; Triazoles | 2022 |
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Benzodiazepines; Child; Communication; Double-Blind Method; Humans; Male; Pyridines; Treatment Outcome; Triazoles | 2022 |
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
Topics: Adaptation, Psychological; Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Autism Spectrum Disorder; Behavior; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pyridines; Quality of Life; Receptors, Vasopressin; Treatment Outcome; Triazoles; Young Adult | 2019 |
3 other study(ies) available for triazoles and Autism Spectrum Disorder
| Article | Year |
|---|---|
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
Topics: Autism Spectrum Disorder; Autistic Disorder; Benzodiazepines; Humans; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2022 |
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.
Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Autism Spectrum Disorder; Benzodiazepines; Brain; Child; Clinical Trials as Topic; Drug Discovery; Female; Humans; Male; Mammals; Pyridines; Receptors, Vasopressin; Triazoles | 2020 |
Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.
Topics: Autism Spectrum Disorder; Azepines; Drug Therapy, Combination; Female; Humans; Indenes; Sleep Aids, Pharmaceutical; Sleep Disorders, Circadian Rhythm; Treatment Outcome; Triazoles; Young Adult | 2020 |